Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
- Conditions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- The Medicines Company
- Registration Number
- NCT04592380
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸New York Methodist Hospital, Brooklyn, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 1617
- Registration Number
- NCT03400800
- Locations
- 🇬🇧
Research Site - 11044-027, Davyhulme, Manchester, United Kingdom
🇬🇧Research Site - 11044-009, Exeter, Devon, United Kingdom
🇿🇦Research Site 11027-003, Bloemfontein, Free State, South Africa
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 1561
- Registration Number
- NCT03399370
- Locations
- 🇺🇸
Research Site 10001-069, Atlanta, Georgia, United States
🇺🇸Research Site 10001-158, Chicago, Illinois, United States
🇺🇸Research Site 10001-035, Chicago, Illinois, United States
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
- Conditions
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 482
- Registration Number
- NCT03397121
- Locations
- 🇺🇸
Site 90001-047, Boca Raton, Florida, United States
🇨🇦Site 90011-005, Chicoutimi, Quebec, Canada
🇺🇸Site 90001-005, Mission Viejo, California, United States
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 31
- Registration Number
- NCT03159416
- Locations
- 🇳🇿
Auckland Clinical Studies Limited, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 9
- Registration Number
- NCT02963311
- Locations
- 🇺🇸
Research Site 201001, Los Angeles, California, United States
🇳🇱Research Site 231001, Amsterdam, Netherlands
🇿🇦Research Site 227001, Parktown, Johannesburg, South Africa
Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 22
- Registration Number
- NCT02925416
- Locations
- 🇺🇸
South Jersey Infectious Disease, Somers Point, New Jersey, United States
Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT02800590
- Locations
- 🇳🇱
Martini Hospital, Groningen, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
🇳🇱University Medical Center Groningen (UMCG), Groningen, Netherlands
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 126
- Registration Number
- NCT02678923
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 501
- Registration Number
- NCT02597127
- Locations
- 🇳🇱
Admiraal de Ruyter Hospital, Cardiology, Goes, Netherlands
🇨🇦Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada
🇨🇦ECOGENE-21 Clinical Trials Center, Chicoutimi, Quebec, Canada